A suite of community-contributed programs to produce outcome tables and graphs for demographic and survival data Not theory-heavy, Stata-heavy or anything.

Slides:



Advertisements
Similar presentations
The analysis of survival data in nephrology. Basic concepts and methods of Cox regression Paul C. van Dijk 1-2, Kitty J. Jager 1, Aeilko H. Zwinderman.
Advertisements

Survival Analysis. Key variable = time until some event time from treatment to death time for a fracture to heal time from surgery to relapse.
RELATIVE RISK ESTIMATION IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF METHODS FOR INDEPENDENT OBSERVATIONS Lisa N Yelland, Amy B Salter, Philip Ryan.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Clustered or Multilevel Data
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Using time-dependent covariates in the Cox model THIS MATERIAL IS NOT REQUIRED FOR YOUR METHODS II EXAM With some examples taken from Fisher and Lin (1999)
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
EVIDENCE BASED MEDICINE
Key Performance Indicators, Centre Reports, and more Stephen McDonald.
Survival Analysis Diane Stockton. Survival Curves Y axis, gives the proportion of people surviving from 1 at the top to zero at the bottom, representing.
Are the results valid? Was the validity of the included studies appraised?
Assessing Survival: Cox Proportional Hazards Model
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 2: Diagnostic Classification.
Developments & Issues in the Production of the Summary Hospital-level Mortality Indicator (SHMI) Health and Social Care Information Centre (HSCIC)
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 2: Aging and Survival.
CAT 4: How to Read a Prognosis Article Maribeth Chitkara, MD Rachel Boykan, MD.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Kaplan-Meier Survival Plotting Macro %NEWSURV Jeffrey Meyers Mayo Clinic, Rochester, MN.
Associate Professor, Honorary Consultant Cardiologist
Descriptive statistics (2)
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Instructional Objectives:
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
Study Designs Group Work
Outcomes in AKI, the national audit
Is a Risk Factor for Early Mortality
The Donor Perspective Catherine Burlton Title slide (option number 2)
April 18 Intro to survival analysis Le 11.1 – 11.2
First-year death rates by modality figure 8
Anastasiia Raievska (Veramed)
Present: Disease Past: Exposure
CASE-CONTROL STUDIES Ass.Prof. Dr Faris Al-Lami MB,ChB MSc PhD FFPH
Mortality rates in incident ESRD patients figure 9
Ann Intern Med. 2011;155(8): doi: / Figure Legend:
Table 1 Characteristics of study population, by pneumococcal vaccination status. From: Prior Pneumococcal Vaccination Is Associated with Reduced Death,
UK Renal Registry 18th Annual Report
Survival Curves L.O: to describe and explain the shape of the human population survival curve
Chapter 8: Inference for Proportions
Insert Objective 1 Insert Objective 2 Insert Objective 3.
HS 4160 Critical Scientific Analysis
Peripheral T-Cell Lymphoma in 2013
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Il trapianto allogenico da donatore alternativo dopo condizionamento a ridotta intensità Alessandro Rambaldi.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Date: Presenter: Ryan Chen
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Transplantation rates for living- but not deceased-donor kidneys vary with socioeconomic status in Australia  Blair S. Grace, Philip A. Clayton, Alan.
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review 
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.
Improving the Standards of Reporting of Clinical Trial Data
Donor Cell Leukemia: A Review
Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018
UK Renal Registry 16th Annual Report
Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study Shi Zhao, Karthik.
Clinical Lymphoma, Myeloma and Leukemia
Kantarjian HM et al. Blood 2008;112:Abstract 635.
STEPS Site Report.
Dialysis outcomes in Australia & New Zealand
Survival of End Stage Renal Failure Patients with Cancer
Kaplan-Meier survival curves and the log rank test
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
Presentation transcript:

A suite of community-contributed programs to produce outcome tables and graphs for demographic and survival data Not theory-heavy, Stata-heavy or anything heavy. Just going to show how I have used Stata to make my life a bit easier and to provide quick, but reasonably robust, answers to questions. Rachel Pearce British Society of Blood and Marrow Transplantation Guy’s Hospital

Background BSBMT is an organisation for professionals with an interest in haematopoeitic stem cell transplantation Registry of all transplants performed in UK (subject to consent) + some Republic of Ireland Data mostly used for retrospective studies, e.g. Comparison of chemotherapy Whether the procedure is practical in certain circumstances (age / comorbidity / disease) Whether a second transplant is useful in the event of relapse after a first one These retrospective studies are methodically set up, data are checked and analyses are rigorously performed Used to be called bone marrow transplantation. Now peripheral blood too. Also a few umbilical cord blood. Consent mostly (99%) given Prospective studies handled by another body, but often informed by data we supply NHSE commissions stem cell transplants at regional level because they are relatively rare (3800 in England, 275 in Scotland, 150 in Wales, 60 in N Ireland)

Requests from NHSE for summaries of data Routine and ad hoc e.g. How many transplants of a given type in the last 5 years? How many of these were from sibling donors? How many had Reduced Intensity Conditioning? What ages were they? How many are still alive? How many died from non-relapse cause? 4 Please tell me you’re not going to divide the number alive by the total to get a survival rate are you? “Errr…” I will do a survival curve for you 6 Quickly becomes time-consuming, but also error-prone if I am doing a lot of them in succession E.g. easy to mislabel a graph if you are doing 20 of them

Two sorts of programs developed Programs to generate datasets: take Registry data and create summary tables as Stata datasets Programs to generate outputs: combine these datasets into datasets suitable for output to a Word file via putdocx Version 15 Stata

Programs to generate datasets All generate values for each level of the factor and for the total medianbyfactor : medians of e.g. age or time to discharge from hospital binarybyfactor : numbers and percentages of a given binary variable osbyfactor : overall survival and 95% confidence interval at various time points nrmbyfactor : as for osbyfactor but for non-relapse mortality fubyfactor : as for osbyfactor but for follow up 3 By Cox model. Can be adjusted by covariates e.g. comorbidity or unadjusted 4 By competing risks regression 5 also by cox model (unadjusted) 6, 7 You can imagine how excited I was by Version 15 and “putdocx”

Example program: osbyfactor

Programs to generate output These programs use output from osfactor etc. and combine them: factortables : combine some of the above into a table showing demographic and outcome data factorgraph : produces a graph comparing two levels of a factor giving Ns and P values tablegraph : produces a table (calling factortable) and overall survival (OS) graph for the same factor, appropriately labelled centregraphs : to produce OS curves comparing a centre with the rest of the Registry P values are according to Cox model with fixed covariates (age and comorbidity) and stratified by diagnosis and type of transplant, but I am looking at making the covariates arguments of the function

Example 1: Prospective trial proposed to discover the prognostic value of a particular test Specific population with a particular diagnosis Test only recently available; presence of indicator is speculated to have poor prognosis Trial design to establish this requires estimate of 2y OS in each case I was able to swiftly estimate the baseline survivals in the two subpopulations and graphically illustrate them Recent actual request from our sister body which performs prospective trials Obviously a third option is “test not performed or no definitive outcome” but these are not of interest to this specific request

Autologous transplant patients by prognostic status Prognostic marker Absent Present Total 124 86 210 Alive in CCR 102 57 159 Alive post relapse 15 16 31 Relapse death 4 7 11 Non relapse death 3 6 9 Engraftment failure 17 28 % engraftment failure 14 13 Median engraftment time (d) 12 % OS at 1y 93 88 91 95% c.i. min 85 77 95% c.i. max 97 94 95 % OS at 2y 81 87 65 79 90 % NRM at 100d 5 1 2 % NRM at 1y 20 % NRM at 2y Autologous transplant patients by prognostic status Output from tablegraph

OS by prognostic marker

Example 2: Outcomes by centre Asked to report numbers and outcomes by centre, by diagnosis and by type of transplant Need to compare outcomes with UK standard Reasonable comparisons require stratification / risk adjustment Recent request from NHSE / other NHS bodies 53 centres, 2 age groups, up to 20 diagnostic groups (

From centre report One centre Specific diagnosis Specific procedure Outcomes of Cox regressions inform notes Background colours for notes changed to reflect good / bad FU or OS This sort of thing (plus the associated tables) is repeated for each diagnosis, age group (adult/paediatric) and procedure (autologous or allogeneic transplant) to give an overview of

Thanks Rest of the Registry Team Physicians and Data Managers at all the centres which contribute data Fellow Stata users on Statalist and Twitter Patients who consent for their data to be used Rachel Pearce, Guy’s Hospital rachel.pearce@kcl.ac.uk